Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.

@article{Caro2000EconomicAO,
  title={Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.},
  author={J. Jaime Caro and Wendy S. Klittich and Gabriel Raggio and Patricia L Kavanagh and J A O'brien and L A Shomphe and Kenneth M. Flegel and Catherine Copley-Merriman and C J Sigler},
  journal={Clinical therapeutics},
  year={2000},
  volume={22 1},
  pages={116-27}
}
OBJECTIVE To assess the economic efficiency of adding troglitazone to sulfonylurea therapy to improve glycemic control. BACKGROUND Despite the high prevalence of type 2 diabetes, existing treatment strategies often fail. New oral agents give a wider segment of the population with type 2 diabetes hope of achieving near-normal blood-glucose levels. Troglitazone, a novel chemical entity, is one promising new agent. METHODS We conducted an economic analysis based on glycemic-control data from a… CONTINUE READING
12 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…